Compare AbbVie Inc (ABBV) vs 8x8 Inc (EGHT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

EGHT (8x8, Inc.) trades at $1.94, up 6.01% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 EPS versus $0.07 expected. Recent news highlights AI product launches and industry recognition, including being named a 2026 MetriStar Top Provider for CPaaS. However, the company reported a net loss of $27.21 million for 2025, though projections show potential profitability improvement in 2026.

The outlook remains cautiously optimistic with analyst consensus showing 39% buy ratings but mixed technical indicators. Key opportunities include continued AI product adoption and revenue growth momentum, while risks center on profitability challenges, high debt levels, and competitive pressures in the communications platform market.